Purpose {#Sec1}
=======

A large fraction of currently marketed pharmaceuticals act via G protein-coupled receptors (GPCRs), and understanding recognition and function of GPCRs at a precise molecular level is essential for future drug discovery (Jacobson & Costanzi [@CR13]). Action of a drug via a GPCR is either through direct binding to the receptor (as orthosteric agonist or antagonist or as allosteric modulator) or by affecting the levels of the endogenous transmitter that are available to activate it. Among the many naturally-occurring extracellular signaling molecules, nucleosides and nucleotides serve to both modulate biological processes in many organs and tissues and to maintain homeostasis. In addition to their many intracellular functions and ion channel activation, these ubiquitous signaling molecules act outside the cell through GPCRs. These receptors include eight subtypes of P2Y receptors (P2YRs), which are all activated by nucleotides but not nucleosides, and four subtypes of adenosine receptors (ARs). The increased release and production of extracellular nucleotides and adenosine, which are localized rather than systemic, are typically a direct function of stress to an organ or tissue, such as hypoxia (Chen et al. [@CR3]). The resulting elevated level of endogenous agonist increases a tonic activation of one or more of these receptors to produce a protective response. In some cases, such as the adenosine "halo" surrounding tumor cells (Antonioli et al. [@CR1]), the protective response is undesired clinically, and in which case an antagonist might be more applicable therapeutically. Nucleotide action through P2YRs tends to boost the innate immune system, i.e. the immediate defensive response.

There is renewed interest in developing AR or P2YR modulators for therapeutic use, due to recent advances in understanding the related biological processes and increased structural knowledge of the receptors. We and other labs are exploring structure-activity relationships (SAR) at ARs and P2YRs, in order to synthesize and characterize selective agents as pharmacological probes and as potential therapeutic agents. We emphasize four aspects of studying these receptors: 1) design and synthesis of novel and selective agonists and antagonists to expand the SAR; 2) structure-function studies of the receptor proteins; 3) exploration of the novel biological role of such receptors; and 4) conceptualization of future therapeutics. In this effort, there is a tight coupling of organic synthetic methodology, molecular modeling, structural biology, and pharmacology.

Main text and discussion {#Sec2}
========================

We are designing more potent and subtype-selective receptor ligands, based on an understanding of the molecular recognition in the binding site. New insights into drug design are derived from the X-ray crystallographic structures of GPCRs (Jacobson & Costanzi [@CR13]), and ARs are at the forefront of this effort (Jaakola et al. [@CR11];Dore et al. [@CR7];Xu et al. [@CR26]). Although few compounds that act at these two receptor families are approved for clinical use, the ARs serve as important test cases for structure-based ligand design for GPCRs in general. Since 2008, the availability of X-ray crystallographic structures of the human A~2A~AR in complex with xanthine and non-xanthine antagonists (Jaakola et al. [@CR11];Dore et al. [@CR7]), has allowed more precise molecular modeling of the 3 dimensional structures of the A~2A~AR and related receptors with other bound ligands. Recently, a very high resolution structure of an antagonist-bound A~2A~AR (1.8 Å) was reported and shown to predict allosteric interactions at a site deeper than the orthosteric ligand binding region (Liu et al. [@CR20];Gutiérrez-de-Terán et al. [@CR9]). The accuracy of many previous AR modeling and docking studies (Ivanov et al. [@CR10]) is a fortuitous result of the close structural similarity of ARs and rhodopsin, the GPCR used for nearly a decade as the most closely related protein template for modeling Family A GPCRs.

In 2011, the first crystal structure of the A~2A~AR bound to an agonist, i.e. the highly substituted nucleoside UK432,097 1 (Figure [1](#Fig1){ref-type="fig"}), was determined by Raymond Stevens and coworkers at Scripps Research Inst. (Xu et al. [@CR26]), and similar structures of the A~2A~AR in complex with adenosine and its mono-substituted derivative (NECA, 2) were determined by Lebon et al. at MRC Laboratory of Molecular Biology in Cambridge, UK and Heptares Therapeutics (Lebon et al. [@CR19]). The structures of Lebon et al., which additionally show portions of the second extracellular loop (EL2) not defined in the UK432,097 complex, were determined using receptors with thermostabilizing point mutations (StaRs). All agonist-bound A~2A~AR structures show similar interactions involving the adenine core and the ribose ring with the receptor. Moreover, the UK432,097 complex is stabilized by multiple H-bonding, van der Waals and hydrophobic interactions on extended C2 and N^6^ substituents. The agonist interactions within the A~2A~AR evident in the X-ray structures are shown below:Figure 1**Two of the AR agonists that were co-crystallized with the human A** ~**2A**~ **AR (1, 2) and agonists selective for the A** ~**2A**~ **AR (3, 4) and A** ~**1**~ **AR (5).**

Comparison of agonist-bound and inactive conformations of the A~2A~AR have largely validated previous approaches to homology modeling of ARs and indicated the conformational changes needed for receptor activation, particularly within the ligand binding region. These conformational changes include a tightening of hydrophilic residues in TM3, TM5 and TM7 around the ribose moiety, which is known to form the "message" portion of the molecule (Xu et al. [@CR26]). Many of the hydrogen bonds with ligand found in the agonist-bound A~2A~AR structures were predicted by earlier molecular modeling (Ivanov et al. [@CR10]). Upon binding of nucleoside agonists to the ARs, unstable water molecules that appear in the inactive state of the A~2A~AR (Jaakola et al. [@CR11];Dore et al. [@CR7]) are expelled from deep in the binding site. The more hydrophobic adenine moiety, which may be derivatized at the C2 and N^6^ positions with other mainly hydrophobic groups that extend further into the EL region, is considered the "address" portion of adenosine, with respect to receptor subtype selectivity. Some of the movements of ELs are specific to accommodate sterically bulky groups of UK432,097 and are less pronounced in other agonist-bound A~2A~AR structures. The implications for receptor signaling by particular agonists that produce their own distinct conformational changes of the A~2A~AR are not yet known.

Pharmacophore-based searches have yielded ligands having novel chemotypes, such as diverse heterocyclic antagonists of the A~2A~AR, a target for Parkinson's disease (de Lera Ruiz et al. [@CR6]). An inactive state structure of the A~2A~AR was applied to *in silico* searches of diverse chemical libraries to identify antagonists of several AR subtypes. This approach has been useful for discovery of antagonists at both the A~2A~AR (Katritch et al. [@CR15];Carlsson et al. [@CR2];van der Horst et al. [@CR25];Congreve et al. [@CR4];Langmead et al. [@CR18]) and the closely related A~1~ and A~3~ARs, by homology. Four separate homology models of the human A~1~AR were built based on optimization with different bound (known) ligands of that subtype, and 2.2 million lead-like compounds were docked in all four models (Kolb et al. [@CR16]). In this study, initially targeting the A~1~AR, 39 *in silico* hits were obtained and subsequently screened in binding to three AR subtypes, resulting in the following percent of successful antagonist hits identified: 21% (A~1~), 38% (A~2A~) and 36% (A~3~). Thus, this docking approach is useful for discovery of hits at the A~1~AR and at closely related subtypes. Some of the successful hits bound to two or three AR subtypes.

Beyond screenings for novel chemotypes, the structures of the A~2A~AR have also proved useful to design improved analogs of the existing ligands. Previous efforts to develop AR agonists for therapeutic use have faced efficacy issues and low selectivity, leading to side effects (Chen et al. [@CR3]). Two agonists of the A~3~AR that were first synthesized and characterized biologically in our lab are already in advanced clinical trials for inflammatory diseases (IB-MECA, 3) and liver cancer (the 2-chloro analogue of IB-MECA, CF102). Current or planned trials of A~3~AR agonists are for treatment of hepatocellular cancer, rheumatoid arthritis, psoriasis, dry eye syndrome, and other inflammatory conditions. Moreover, selective A~1~AR agonists are sought as antiseizure agents, analgesics and for other neuroprotective functions (Luongo et al. [@CR21]). Structural insights, enabled by molecular modeling, have guided the introduction of novel adenosine derivatives as A~1~ and A~3~AR agonists. A first step to validation of the AR agonist modeling approach was to apply it to the A~2A~AR, used as template, and then to extend it to the closely related A~1~ and A~3~AR by homology. Molecular modeling of agonist binding has been evaluated in light of the crystallographic structure of the agonist-bound A~2A~AR and found to predict interactions of 20 known nucleoside ligands (Deflorian et al. [@CR5]).

Ligand docking and fragment searching are useful for suggesting new congeners of known AR agonists and antagonists to be synthesized in order to explore distinct subpockets in the binding site. Our structure-based synthesis of adenosine agonists guided by knowledge of the X-ray structure treated each region of the nucleoside using a different approach. For example, binding affinities following distal changes on an extended C2 chain correlated with predicted interactions in the spatially permissive EL region (Deflorian et al. [@CR5]). In contrast, an exploration of the relatively small subpocket of the agonist-bound A~2A~AR structure surrounding the 5′ substituent of ribose yielded novel 5′-amide derivatives, similar to NECA (Tosh et al. [@CR24]). The ethyl group of NECA was replaced with small (MW \< 150) but diverse molecular fragments to complement this subpocket. The majority of *in silico* hits that were high ranking energetically (roughly the top 1% of a set of 2000 screened structures) and tested in binding assays indeed bound with submicomolar K~i~ values at the A~2A~AR. When the inactive A~2A~AR structure (3EML) was used for screening these adenosine analogues with diverse 5′-amide fragments, the statistical advantage shown in the receiver operating characteristic (ROC) curve (Figure [2](#Fig2){ref-type="fig"}), clearly evident using the agonist-bound A~2A~AR structure (3QAK), disappeared. When an intermediate conformational model (agonist-optimized 3EML) was used for screening, modified from the inactive state through docking of an agonist and relaxing of side chains, the ROC predictability was also intermediate. Virtual hits that more potently inhibited radioligand binding at the A~1~AR than the A~2A~AR were rationalized based on specific H-bonding interactions with residues of the A~1~AR as predicted in the modeling.Figure 2**Performance of virtual screening of amide fragment derivatives similar to NECA, using three different A** ~**2A**~ **AR models, reprinted with permission from Tosh et al. (Tosh et al.** [@CR24] **).**

A comparison of the ribose binding elements of the A~2A~AR with the corresponding amino acid residues in other subtypes shows more significant variation in the A~3~AR than in the A~1~AR. Affinity (but not efficacy in receptor activation) of nucleosides at the A~3~AR seems to depend more heavily on factors outside the ribose binding pocket than is the case for other AR subtypes. This hypothesis is supported by many adenosine analogues lacking the 5′-amide group entirely, i.e. truncated at the 4′ carbon that still bind potently to the A~3~AR (Tosh et al. [@CR23]). Nevertheless, the tetrahydrofuryl core scaffold of ribose, or an isostere thereof, is still important at the A~3~AR as for other AR subtypes.

The latest generation of A~3~AR receptor agonists contains a constrained bicyclic (bicyclo\[3.1.0\]hexane, known as methanocarba) substitution of ribose to maintain a receptor-preferred North (N) conformation (Tosh et al. [@CR22]). This rigid ring system (fused cyclpentane and cyclopropane rings) in its two isomeric forms, i.e. either (N) or South (S), as applied to nucleosides was used before any structural elucidation to interrogate the ribose conformation when bound to an AR (as ribose in adenosine can readily twist to adopt a range of conformations) (Jacobson et al. [@CR12]). The adenosine analogue having a fixed (N) conformation was clearly the more potent isomer at the A~1~AR, A~2A~AR and A~3~AR, with the greatest enhancement over (S) occurring at A~3~AR (155-fold). Indeed, the predicted (N) ribose conformation was verified when the agonist-bound A~2A~AR structures were determined.

We have explored rigidified (N)-methanocarba C2-arylalkynyl nucleoside analogues, such as MRS5698 4, that are highly selective A~3~AR agonists. The very high A~3~AR selectivity (typically \~10,000-fold) in this series of C2-arylalkynyl (N)-methanocarba nucleosides was consistent with a predicted outward movement of the portion of TM2 near the EL region of the A~3~AR, in order to preserve hydrogen-bonding interactions with conserved residues in TMs 3, 5, and 7 that lock the adenosine moiety in its deeper binding pocket. This outward movement of TM2, which is justified based on other activated GPCR structures (opsin and β~2~-adrenergic receptor) is not likely to occur in the A~2A~AR, because the EL region of this AR subtype is conformationally constrained by four disulfide bridges.

A~1~AR agonist MRS5474 5 also contains a constrained bicyclic substitution of ribose to maintain a receptor-preferred North (N) conformation (Tosh et al. [@CR23]). MRS5474 has in vivo anti-convulsant activity without typical rotorod toxicity observed for standard A~1~AR agonists, which are known to produce intense cardiovascular depression. The *N*^6^-dicyclopropylmethyl substitution was selected by screening (in binding assays of the synthetic analogues), in the truncated, methanocarba series, many alkyl/aryl groups known to promote A~1~AR agonism in the ribose series (Tosh et al. [@CR23]). This particular N^6^ group appears to be a structural sweet spot, in that it maintains selectivity and full efficacy. The very tight fit in the N^6^ region in receptor docking has been analyzed through homology modeling of the human A~1~AR, based on the agonist-bound A~2A~AR structure (Xu et al. [@CR26]). Deletion of an otherwise important recognition element (H-bonding groups at the 5′ position) is compensated by a specific N^6^ substitution in MRS5474.

Novel fluorescent and radiolabeled probes and multivalent conjugates of strategically functionalized AR ligands have also been designed with the aid of molecular modeling (Kozma et al. [@CR17]). Such high affinity ligands containing reporter groups are useful tools for the characterization of receptors and their oligomeric assemblies. For example, adenosine agonist binding to the heterodimers formed between the A~2A~AR and D~2~ dopamine receptor can be followed in real time using such a conjugate (Fernández-Dueñas et al. [@CR8]). The interaction of the fluorophore of a given fluorescent chemical probe with the outer portions of the receptor, mainly distal interactions with functional groups on the receptor, may have a major influence on its affinity and selectivity. Thus, the pharmacological profile of the functionalized congener that serves as precursor of the fluorescent ligand is not always predictive of the properties of the final conjugate, and GPCR molecular modeling can provide insight into this phenomenon. One such example is a fluorescent agonist of the P2Y~6~R that was greatly enhanced in potency and selectivity by the addition of an AlexaFluor488 moiety at the end of a flexible chain (Jayasekara et al. [@CR14]). According to receptor modeling, this fluorophore did not escape the outer environment, i.e. the ELs of the P2Y~6~R where they are predicted to anchor to specific sites. In this case, the closer template for homology modeling for the P2YRs was judged to be the CXCR4 structure, rather than the A~2A~AR structure.

Conclusions {#Sec3}
===========

Thus, the 3D knowledge of receptor binding and activation promises to enable drug discovery for GPCRs in general, and specifically for the ARs. The predictability of modeling based on the X-ray structures of the A~2A~AR has been well demonstrated in the design and modification of both known and novel AR agonists and antagonists. *In silico* screening by docking of chemical libraries to these new structures and to closely related receptor homology models has been validated. It is expected that structure-based design of drugs acting through ARs will provide new avenues to clinically useful agents.
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